Navigation Links
On March 4, 2009, The United States Supreme Court Rejected the Rationale Behind Michigan's Drug Product Liability Law
Date:3/4/2009

DETROIT, March 4 /PRNewswire/ -- On March 4, 2009, the United States Supreme Court in the case of Wyeth v. Levine, rejected the drug company's argument that because it was complying with FDA standards it should be immune from suit. Because of this decision, citizens in all states except Michigan can continue to sue drug companies whose products injure the citizens of those states.

During the term of former Governor John Engler, the Republican legislature passed a statute granting immunity to companies (drug companies) whose products are approved by the FDA. That statute which denied Michigan citizens the right to sue for injuries sustained from dangerous drugs was believed by drug companies to set a pattern which would allow the drug companies to deny the citizens in the other 49 states the right to sue.

Using the theory of "Federal Pre-emption" Wyeth told the United States Supreme Court that under the law it could not change its labeling to warn people such as Mrs. Levine that the Wyeth drug Phenergan by the iv - push method had the potential of causing serious injuries and death, including amputation, because the FDA laws did not allow such a change in the warnings. The United States Supreme Court found this to be untrue after analyzing the existing laws.

Two editorials in the leading medical journals, Journal of the American Medical Association and the New England Journal of Medicine, both criticized the attempts of the drug companies to seek immunity and encouraged the United States Supreme Court not to recognize Federal Pre-emption if it meant preventing state court actions against drug companies. The authors of these editorials pointed to the numerous drug products where drug companies hid information about the dangers of drugs that was only uncovered and made available to the medical profession by the filing of state lawsuits which allowed state courts to order drug companies to turn over documents that the drug companies had either hidden from the FDA or mischaracterized to the FDA.

The decision according to Michigan Trial Lawyer, J. Douglas Peters of Charfoos & Christensen, P.C., "This decision may have a sobering impact on the Republicans in the Michigan Senate which should immediately consider reversing Michigan's unique and unfair law to bring Michigan back into line with the law of the other 49 states, as recognized by the United States Supreme Court in its new decision."

According to Peters, "The drug industry had a special friend in Governor Engler, and Governor Engler tried to export his success for the drug companies in Michigan to the national level where he currently works as a lobbyist for various manufacturing interests."

Peters also stated that he " ... hopes the Michigan legislature will act quickly to change Michigan's consumer hostile drug law in light of this new United States Supreme Court decision, to protect the health, safety and welfare of Michigan citizens."

    For more information contact:
    J. Douglas Peters, Esq.
    Charfoos & Christensen, P.C.
    5510 Woodward Avenue
    Detroit, Michigan  48202
    (313) 875-8080


'/>"/>
SOURCE Charfoos & Christensen, P.C.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. National Multiple Sclerosis(MS) Awareness Week is March 15-21
2. AMERIGROUP Corporation to Present at the Barclays Capital Global Healthcare Conference on March 10
3. Clarient Reschedules Fourth Quarter and Year-End 2008 Financial Results Release To Wednesday, March 11th; Conference Call and Webcast Rescheduled For 5:00 PM EDT That Day
4. Cardiogenesis Corporation to Report 2008 Fourth Quarter and Year-End Results on March 31st
5. Air Methods to Report Fourth Quarter and Fiscal Year 2008 Financial Results on Tuesday, March 10, 2009
6. PLC Systems to Host Fourth Quarter Conference Call on March 12, 2009
7. Osteotech Announces Fourth Quarter and Full Year 2008 Earnings Release and Conference Call; Company to Release Financial Results on Wednesday, March 4, 2009 and Host Call on Thursday, March 5, 2009
8. China Nepstar Chain Drugstore to Announce Fourth Quarter and Fiscal 2008 Financial Results on March 16
9. EyeCare America Offers No-Cost Medical Eye Care to Qualified Seniors In Support of National AMD Month - March 2009
10. March Is National Kidney Month
11. Triple-S Management Corporation to Host Inaugural Investor Day on March 5, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... , ... October 13, 2017 , ... The American Board ... become its next President and Chief Executive Officer, succeeding Dr. James C. Puffer upon ... beginning July 1, 2018 until Dr. Puffer’s retirement at the end of 2018. Upon ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... ‘17, and Jennifer Huggins, PharmD ’17, along with clinical associate professor Janice ... of cardiovascular diseases during the 15th Annual Women’s Health Conference. The SIU ...
(Date:10/13/2017)... SAN LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... with Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for ... mean is the 90-day elimination period, when the family pays for care, is often ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th ... Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, ... The fun run is geared towards children of all ages; it is a non-competitive, ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Software Development, has been awarded a contract by the Center for Medicare and ... aims to accelerate the enterprise use of Agile methodologies in a consistent and ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... for their devotion to personalized service, SMP Pharmacy Solutions announces ... the South Florida Business Journal,s 50 Fastest-Growing Companies, and listed ... national specialty pharmacy has found its niche.  To that end, ... honored by SFBJ as the 2017 Power Leader in Health ... his award in October, Bardisa said of the three achievements, ...
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
Breaking Medicine Technology: